AU2015208244B2 - Process for the preparation of N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine - Google Patents

Process for the preparation of N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine Download PDF

Info

Publication number
AU2015208244B2
AU2015208244B2 AU2015208244A AU2015208244A AU2015208244B2 AU 2015208244 B2 AU2015208244 B2 AU 2015208244B2 AU 2015208244 A AU2015208244 A AU 2015208244A AU 2015208244 A AU2015208244 A AU 2015208244A AU 2015208244 B2 AU2015208244 B2 AU 2015208244B2
Authority
AU
Australia
Prior art keywords
formula
acid
compound
process according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015208244A
Other languages
English (en)
Other versions
AU2015208244A1 (en
Inventor
Junli Chen
Yi Ren
Jin She
Lin Wang
Jianhua Yu
Guocai ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2015208244A1 publication Critical patent/AU2015208244A1/en
Application granted granted Critical
Publication of AU2015208244B2 publication Critical patent/AU2015208244B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015208244A 2014-01-24 2015-01-21 Process for the preparation of N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine Active AU2015208244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/071331 2014-01-24
CNPCT/CN2014/071331 2014-01-24
PCT/EP2015/051066 WO2015110446A1 (en) 2014-01-24 2015-01-21 Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine

Publications (2)

Publication Number Publication Date
AU2015208244A1 AU2015208244A1 (en) 2016-06-16
AU2015208244B2 true AU2015208244B2 (en) 2017-11-02

Family

ID=52358790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015208244A Active AU2015208244B2 (en) 2014-01-24 2015-01-21 Process for the preparation of N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine

Country Status (20)

Country Link
US (2) US10005770B2 (cg-RX-API-DMAC7.html)
EP (2) EP3248969B1 (cg-RX-API-DMAC7.html)
JP (1) JP6397501B2 (cg-RX-API-DMAC7.html)
KR (1) KR101841866B1 (cg-RX-API-DMAC7.html)
CN (2) CN109879837B (cg-RX-API-DMAC7.html)
AR (2) AR099134A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015208244B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016016978B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934225C (cg-RX-API-DMAC7.html)
ES (2) ES2788900T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20200715T1 (cg-RX-API-DMAC7.html)
IL (1) IL245882B (cg-RX-API-DMAC7.html)
MX (1) MX368110B (cg-RX-API-DMAC7.html)
MY (1) MY176210A (cg-RX-API-DMAC7.html)
NZ (1) NZ721534A (cg-RX-API-DMAC7.html)
PL (2) PL3097098T3 (cg-RX-API-DMAC7.html)
RU (1) RU2664643C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201605916QA (cg-RX-API-DMAC7.html)
SI (2) SI3097098T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015110446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2017009316A1 (en) 2015-07-16 2017-01-19 F. Hoffmann-La Roche Ag Crystalline forms of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1 -dioxido-1,4-benzothiazepin-4(5 h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
PH12022550783A1 (en) 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2021083290A1 (en) 2019-10-31 2021-05-06 Shanghai Ark Biopharmaceutical Co. Ltd. Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same
CN113149977A (zh) * 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
CN111548325A (zh) * 2020-05-16 2020-08-18 西安都创医药科技有限公司 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111518055A (zh) * 2020-05-16 2020-08-11 西安都创医药科技有限公司 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用
CN111620838A (zh) * 2020-05-16 2020-09-04 西安都创医药科技有限公司 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111574475B (zh) * 2020-06-03 2022-09-20 西安都创医药科技有限公司 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
EP4745139A1 (en) * 2023-07-10 2026-05-20 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. COMPOUND FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES CAUSED BY THE RESPIRATORY SYNCYTIAL VIRUS
WO2026149524A1 (zh) * 2025-01-09 2026-07-16 石药集团中奇制药技术(石家庄)有限公司 氨基吡咯烷类衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
CA2516329A1 (en) * 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
US20050009817A1 (en) * 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
JP4899385B2 (ja) * 2005-09-06 2012-03-21 宇部興産株式会社 3−アミノメチルオキセタン化合物の製法
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
US8871756B2 (en) * 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
JP2014530225A (ja) 2011-10-11 2014-11-17 エフ.ホフマン−ラ ロシュアーゲーF.Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス疾患の処置および予防のための化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184163A1 (en) * 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Also Published As

Publication number Publication date
CA2934225A1 (en) 2015-07-30
JP2017503843A (ja) 2017-02-02
CN106414436A (zh) 2017-02-15
MX2016009514A (es) 2016-10-26
IL245882B (en) 2019-09-26
PL3248969T3 (pl) 2020-06-29
KR20160102055A (ko) 2016-08-26
AR118371A2 (es) 2021-09-29
AU2015208244A1 (en) 2016-06-16
CN106414436B (zh) 2019-04-23
SI3097098T1 (sl) 2020-07-31
RU2016133187A3 (cg-RX-API-DMAC7.html) 2018-02-28
EP3097098B1 (en) 2020-03-04
US10005770B2 (en) 2018-06-26
HRP20200715T1 (hr) 2020-07-24
US10253022B2 (en) 2019-04-09
EP3097098A1 (en) 2016-11-30
BR112016016978B1 (pt) 2022-08-16
NZ721534A (en) 2018-02-23
JP6397501B2 (ja) 2018-09-26
MY176210A (en) 2020-07-24
KR101841866B1 (ko) 2018-03-23
RU2016133187A (ru) 2018-02-28
BR112016016978A2 (cg-RX-API-DMAC7.html) 2017-08-08
SI3248969T1 (sl) 2020-07-31
MX368110B (es) 2019-09-18
EP3248969A1 (en) 2017-11-29
US20180265505A1 (en) 2018-09-20
PL3097098T3 (pl) 2020-06-29
IL245882A0 (en) 2016-08-02
ES2788900T3 (es) 2020-10-23
EP3248969B1 (en) 2020-03-04
US20160326160A1 (en) 2016-11-10
HRP20200680T1 (hr) 2020-07-24
ES2789798T3 (es) 2020-10-26
RU2664643C2 (ru) 2018-08-21
CA2934225C (en) 2018-09-04
AR099134A1 (es) 2016-06-29
CN109879837A (zh) 2019-06-14
SG11201605916QA (en) 2016-08-30
WO2015110446A1 (en) 2015-07-30
CN109879837B (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
EP3248969B1 (en) Process for the preparation of n-[3-(aminomethyl)oxetan-3-yl]carbamate intermediates
EP2367782B1 (en) Process for preparation of ivabradine
CN107922352B (zh) 制备蛋白质脱乙酰酶抑制剂的方法
WO2014020555A2 (en) An improved process for the preparation of dabigatran etexilate mesylate
JP7292517B2 (ja) オキセタン-2-イルメタンアミンの調製のためのプロセスおよび中間体
FR2971507A1 (fr) Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
JP2025061453A (ja) 1,5-ベンゾチアゼピン化合物を製造するための方法
AU2004205494B2 (en) Piperazine derivatives and their use as synthesis intermediates
US20090023925A1 (en) N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
HK1231875A1 (en) Process for the preparation of compound for prophylaxis and treatment of rsv
WO2021170719A1 (en) Process for the preparation of panobinostat
EP3600298A1 (en) Synthetic processes and synthetic intermediates
HK1231875B (en) Process for the preparation of compound for prophylaxis and treatment of rsv
WO2018130942A1 (en) A process for the preparation of phenoxybenzamine
HU207987B (en) Process for producing 4-ethyl-2-/hydroxy-imino/-5-nitro-3-hexenamide
EP2456758A1 (en) A process for preparing trisubstituted phenyl derivatives comprising a (1h-1,2,4-triazol-1-yl)alkyl group

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)